Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intrace...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Hong Yun, Das, Jeeban, Prendergast, Conor, De Jong, Dorine, Braumuller, Brian, Paily, Jacienta, Huang, Sophia, Liou, Connie, Giarratana, Anna, Hosseini, Mahdie, Yeh, Randy, Capaccione, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670348/
https://www.ncbi.nlm.nih.gov/pubmed/37998743
http://dx.doi.org/10.3390/cimb45110566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670348/
https://www.ncbi.nlm.nih.gov/pubmed/37998743
http://dx.doi.org/10.3390/cimb45110566

Ejemplares similares